RECEIVED
CENTRAL FAX CENTER
SEP 05 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Previously presented) A compound of Formula I: ~~, or a pharmaceutically acceptable salt thereof~~



I

or a pharmaceutically acceptable salt thereof, wherein:

~~wherein~~ R^1 is selected from the group consisting of H, Cl, F, and C_{1-4}alkyl, where C_{1-4}alkyl is optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R^2 is selected from the group consisting of H, Cl, F, C_{1-4}alkyl, OC_{1-4}alkyl, and $-S(O)_2CH_3$, where C_{1-4}alkyl and OC_{1-4}alkyl are optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R^3, R^4 and R^5 are independently selected from the group consisting of hydrogen, F, Cl, C_{1-3}alkyl, and $-OC_{1-3}$alkyl, where C_{1-3}alkyl and $-OC_{1-3}$alkyl are optionally substituted with 1-3 halogens independently selected from F and Cl;

X and Y are each independently selected from the group consisting of O, S, SO, and SO_2; and

n represents an integer selected from 1, 2, 3, and 4.

Claim 2 (Previously presented) The compound according to Claim 1 wherein R^2 is selected from H, F, $-OC_{1-3}$ alkyl, and $-S(O)_2CH_3$, where $-OC_{1-3}$ alkyl is optionally substituted with 1-3 F atoms.

Claim 3 (Previously presented) The compound according to Claim 1, wherein
R^1 is selected from Cl and n-propyl;
R^2 is selected from H and F; and
R^3, R^4 and R^5 are H.

Claim 4 (Previously presented) The compound according to Claim 1, wherein R^2 is $-OCH_2CH_3$ or $-OCH_2CF_3$.

Claim 5 (Previously presented) The compound according to Claim 1, wherein R^5 is H; and R^3 and R^4 are each independently selected from H, F, CH_3, CF_3, $-OCH_3$, $-OCF_3$, $-OCH_2CH_3$ and $-OCH_2CF_3$.

Claim 6 (Previously presented) The compound according to Claim 1, wherein X and Y are each independently selected from O and S.

Claim 7 (Previously presented) The compound according to Claim 1, wherein X and Y are each O.

Claim 8 (Previously presented) The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is meta to the sulfonamide group.

Claim 9 (Previously presented) The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is para to the sulfonamide group.

Claim 10 (Previously presented) The compound according to Claim 1, wherein n is 1-3.

Claim 11 (Previously presented) The compound according to Claim 1, wherein n is 3 or 4.

Claim 12 (Previously presented) The compound according to Claim 1, wherein X and Y are O; n is an integer selected from 1-3; R^3, R^4 and R^5 are H; R^1 is selected from n-propyl and Cl; and R^2 is selected from H, F, and $-S(O)_2CH_3$.

Claim 13 (Previously presented) The compound according to Claim 1, wherein R^1 is C_{2-3} alkyl, which is optionally substituted with 1-3 F atoms.

Claim 14 (Previously presented) The compound according to Claim 1, wherein R^1 is n-propyl.

Claim 15 (Previously presented) The compound which is selected from the compounds below, or a pharmaceutically acceptable salt thereof:


,


,


,


,


,


,


,


, and


.

Claim 16 (Original) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 17 (Original) A method for treating hyperglycemia in a mammalian or human patient having non-insulin dependent (Type 2) diabetes mellitus which comprises administering to said patient a therapeutically effective amount of a compound of Claim 1.

Claims 18-33 (Canceled)